Antineoplastics
1
Reactions 1255 - 6 Jun 2009 Antineoplastics Onycholysis, anaphylaxis and erythrodysaesthesia: case report During treatment for metastatic breast cancer, a woman [age not clearly stated] developed 20-nail onycholysis and leukonychia with paclitaxel that recurred following treatment with docetaxel (but at that time spared the nails of a paretic hand); in addition, she developed anaphylaxis during treatment with carboplatin, and erythrodysaesthesia during capecitabine therapy. At age 48 years, the woman was referred for evaluation of a nail disorder. Previous chemotherapy had included treatment with docetaxel and, following disease progression, paclitaxel 80 mg/m 2 [frequency not stated] and carboplatin [dosage not stated] were started. Over the following 3 months, she developed onycholysis and leukonychia in 20 nails, attributed to paclitaxel. Paclitaxel was stopped and the woman’s onychopathy resolved. Carboplatin was replaced by trastuzumab owing to an anaphylactic reaction [duration of treatment before reaction onset not stated] and in June 2006, capecitabine was added due to clinical progression. In December 2006, as a result of a brain metastasis, she developed a progressive left upper body hemiplegia that included her hand. In December 2007, capecitabine was replaced with docetaxel 100 mg/m 2 every 3 weeks plus lapatinib due to erythrodysaesthesia and clinical progression. Six months after docetaxel was introduced, she developed onycholysis and leukonychia affecting all nails except those of her left paretic hand. She died 3 months later due to clinical progression. Author comment: "Our patient developed onychopathy due to docetaxel after having developed it previously with paclitaxel (onycholysis and leukonychia in both cases). . . We believe that the absence of trauma in an immobile arm allows the avoidance of onycholysis or subungual haematomas". Truchuelo M, et al. Unilateral taxane-induced onychopathy in a patient with a brain metastasis. Dermatology Online Journal 15: 7, No. 3, 15 Mar 2009 - Spain 801141756 1 Reactions 6 Jun 2009 No. 1255 0114-9954/10/1255-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1255 - 6 Jun 2009
Antineoplastics
Onycholysis, anaphylaxis anderythrodysaesthesia: case report
During treatment for metastatic breast cancer, a woman[age not clearly stated] developed 20-nail onycholysis andleukonychia with paclitaxel that recurred followingtreatment with docetaxel (but at that time spared the nailsof a paretic hand); in addition, she developed anaphylaxisduring treatment with carboplatin, and erythrodysaesthesiaduring capecitabine therapy.
At age 48 years, the woman was referred for evaluationof a nail disorder. Previous chemotherapy had includedtreatment with docetaxel and, following diseaseprogression, paclitaxel 80 mg/m2 [frequency not stated] andcarboplatin [dosage not stated] were started. Over thefollowing 3 months, she developed onycholysis andleukonychia in 20 nails, attributed to paclitaxel.
Paclitaxel was stopped and the woman’s onychopathyresolved. Carboplatin was replaced by trastuzumab owingto an anaphylactic reaction [duration of treatment beforereaction onset not stated] and in June 2006, capecitabinewas added due to clinical progression. In December 2006,as a result of a brain metastasis, she developed aprogressive left upper body hemiplegia that included herhand. In December 2007, capecitabine was replaced withdocetaxel 100 mg/m2 every 3 weeks plus lapatinib due toerythrodysaesthesia and clinical progression. Six monthsafter docetaxel was introduced, she developed onycholysisand leukonychia affecting all nails except those of her leftparetic hand. She died 3 months later due to clinicalprogression.
Author comment: "Our patient developed onychopathydue to docetaxel after having developed it previously withpaclitaxel (onycholysis and leukonychia in both cases). . . Webelieve that the absence of trauma in an immobile armallows the avoidance of onycholysis or subungualhaematomas".Truchuelo M, et al. Unilateral taxane-induced onychopathy in a patient with abrain metastasis. Dermatology Online Journal 15: 7, No. 3, 15 Mar 2009 -Spain 801141756
1
Reactions 6 Jun 2009 No. 12550114-9954/10/1255-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
